Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial

Detalhes bibliográficos
Autor(a) principal: Gobo-Oliveira, Mariele [UNESP]
Data de Publicação: 2018
Outros Autores: Pigari, Vitória G [UNESP], Ogata, Matheus Sp [UNESP], Miot, Hélio A [UNESP], Ponce, Daniela [UNESP], Abbade, Luciana Pf [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.1684/ejd.2018.3356
http://hdl.handle.net/11449/188334
Resumo: BACKGROUND: Uremic pruritus is a common symptom in chronic renal failure patients with undefined pathophysiology. Initial treatment involves topical therapy mainly in the form of moisturizers, however, in many cases, this is not sufficient to relieve itching. Systemic adjuvant therapy is therefore necessary, which commonly includes oral antihistamines, with limited success. Positive effects have been reported for gabapentin. OBJECTIVES: To evaluate the efficacy and safety of gabapentin vs. dexchlorpheniramine in reducing uremic pruritus. MATERIALS & METHODS: A randomized, controlled, double-blinded clinical trial for haemodialysis patients with persistent pruritus was performed. Pre-randomisation, cold cream was used for 15 days by 71 participants. Those with pruritus who remained in the study (60 patients) were randomised to receive gabapentin (30 patients; GABA group) or dexchlorpheniramine (30 patients; DEX group) for 21 days. The primary outcome was the decrease in pruritus score and improvement in quality of life. RESULTS: After cold cream use, the participants demonstrated a 37.5% median reduction in Visual Analogue Scale (p<0.01) and a 50% reduction in Quality of Life in Dermatology (DLQI) score (p<0.01). There was an additional reduction of pruritus in both groups (p<0.01), with no difference between the two (p>0.7). The median DLQI was reduced from 2 to 1 in the GABA group and from 2 to 0 in the DEX group. Nineteen patients (32%) reported mild/moderate side effects without differences between the groups. CONCLUSIONS: Uremic pruritus was reduced upon treatment with gabapentin or dexchlorpheniramine with good safety profiles; no difference was observed between the two treatments.
id UNSP_a1cf9528817a0552f8613cfdcb43b14a
oai_identifier_str oai:repositorio.unesp.br:11449/188334
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trialcold creamdexchlorpheniraminegabapentinhaemodialysisuremic pruritusBACKGROUND: Uremic pruritus is a common symptom in chronic renal failure patients with undefined pathophysiology. Initial treatment involves topical therapy mainly in the form of moisturizers, however, in many cases, this is not sufficient to relieve itching. Systemic adjuvant therapy is therefore necessary, which commonly includes oral antihistamines, with limited success. Positive effects have been reported for gabapentin. OBJECTIVES: To evaluate the efficacy and safety of gabapentin vs. dexchlorpheniramine in reducing uremic pruritus. MATERIALS & METHODS: A randomized, controlled, double-blinded clinical trial for haemodialysis patients with persistent pruritus was performed. Pre-randomisation, cold cream was used for 15 days by 71 participants. Those with pruritus who remained in the study (60 patients) were randomised to receive gabapentin (30 patients; GABA group) or dexchlorpheniramine (30 patients; DEX group) for 21 days. The primary outcome was the decrease in pruritus score and improvement in quality of life. RESULTS: After cold cream use, the participants demonstrated a 37.5% median reduction in Visual Analogue Scale (p<0.01) and a 50% reduction in Quality of Life in Dermatology (DLQI) score (p<0.01). There was an additional reduction of pruritus in both groups (p<0.01), with no difference between the two (p>0.7). The median DLQI was reduced from 2 to 1 in the GABA group and from 2 to 0 in the DEX group. Nineteen patients (32%) reported mild/moderate side effects without differences between the groups. CONCLUSIONS: Uremic pruritus was reduced upon treatment with gabapentin or dexchlorpheniramine with good safety profiles; no difference was observed between the two treatments.Nursing Department Botucatu Medical School São Paulo State University (UNESP)Department of Dermatology and Radiotherapy Botucatu Medical School São Paulo State University (UNESP)Department of Medical Clinic Nephrology Botucatu Medical School São Paulo State University (UNESP)Nursing Department Botucatu Medical School São Paulo State University (UNESP)Department of Dermatology and Radiotherapy Botucatu Medical School São Paulo State University (UNESP)Department of Medical Clinic Nephrology Botucatu Medical School São Paulo State University (UNESP)Universidade Estadual Paulista (Unesp)Gobo-Oliveira, Mariele [UNESP]Pigari, Vitória G [UNESP]Ogata, Matheus Sp [UNESP]Miot, Hélio A [UNESP]Ponce, Daniela [UNESP]Abbade, Luciana Pf [UNESP]2019-10-06T16:04:46Z2019-10-06T16:04:46Z2018-08-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article488-495http://dx.doi.org/10.1684/ejd.2018.3356European journal of dermatology : EJD, v. 28, n. 4, p. 488-495, 2018.1952-4013http://hdl.handle.net/11449/18833410.1684/ejd.2018.33562-s2.0-85056280353Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengEuropean journal of dermatology : EJDinfo:eu-repo/semantics/openAccess2024-08-15T18:47:46Zoai:repositorio.unesp.br:11449/188334Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-15T18:47:46Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial
title Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial
spellingShingle Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial
Gobo-Oliveira, Mariele [UNESP]
cold cream
dexchlorpheniramine
gabapentin
haemodialysis
uremic pruritus
title_short Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial
title_full Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial
title_fullStr Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial
title_full_unstemmed Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial
title_sort Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial
author Gobo-Oliveira, Mariele [UNESP]
author_facet Gobo-Oliveira, Mariele [UNESP]
Pigari, Vitória G [UNESP]
Ogata, Matheus Sp [UNESP]
Miot, Hélio A [UNESP]
Ponce, Daniela [UNESP]
Abbade, Luciana Pf [UNESP]
author_role author
author2 Pigari, Vitória G [UNESP]
Ogata, Matheus Sp [UNESP]
Miot, Hélio A [UNESP]
Ponce, Daniela [UNESP]
Abbade, Luciana Pf [UNESP]
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual Paulista (Unesp)
dc.contributor.author.fl_str_mv Gobo-Oliveira, Mariele [UNESP]
Pigari, Vitória G [UNESP]
Ogata, Matheus Sp [UNESP]
Miot, Hélio A [UNESP]
Ponce, Daniela [UNESP]
Abbade, Luciana Pf [UNESP]
dc.subject.por.fl_str_mv cold cream
dexchlorpheniramine
gabapentin
haemodialysis
uremic pruritus
topic cold cream
dexchlorpheniramine
gabapentin
haemodialysis
uremic pruritus
description BACKGROUND: Uremic pruritus is a common symptom in chronic renal failure patients with undefined pathophysiology. Initial treatment involves topical therapy mainly in the form of moisturizers, however, in many cases, this is not sufficient to relieve itching. Systemic adjuvant therapy is therefore necessary, which commonly includes oral antihistamines, with limited success. Positive effects have been reported for gabapentin. OBJECTIVES: To evaluate the efficacy and safety of gabapentin vs. dexchlorpheniramine in reducing uremic pruritus. MATERIALS & METHODS: A randomized, controlled, double-blinded clinical trial for haemodialysis patients with persistent pruritus was performed. Pre-randomisation, cold cream was used for 15 days by 71 participants. Those with pruritus who remained in the study (60 patients) were randomised to receive gabapentin (30 patients; GABA group) or dexchlorpheniramine (30 patients; DEX group) for 21 days. The primary outcome was the decrease in pruritus score and improvement in quality of life. RESULTS: After cold cream use, the participants demonstrated a 37.5% median reduction in Visual Analogue Scale (p<0.01) and a 50% reduction in Quality of Life in Dermatology (DLQI) score (p<0.01). There was an additional reduction of pruritus in both groups (p<0.01), with no difference between the two (p>0.7). The median DLQI was reduced from 2 to 1 in the GABA group and from 2 to 0 in the DEX group. Nineteen patients (32%) reported mild/moderate side effects without differences between the groups. CONCLUSIONS: Uremic pruritus was reduced upon treatment with gabapentin or dexchlorpheniramine with good safety profiles; no difference was observed between the two treatments.
publishDate 2018
dc.date.none.fl_str_mv 2018-08-01
2019-10-06T16:04:46Z
2019-10-06T16:04:46Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1684/ejd.2018.3356
European journal of dermatology : EJD, v. 28, n. 4, p. 488-495, 2018.
1952-4013
http://hdl.handle.net/11449/188334
10.1684/ejd.2018.3356
2-s2.0-85056280353
url http://dx.doi.org/10.1684/ejd.2018.3356
http://hdl.handle.net/11449/188334
identifier_str_mv European journal of dermatology : EJD, v. 28, n. 4, p. 488-495, 2018.
1952-4013
10.1684/ejd.2018.3356
2-s2.0-85056280353
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv European journal of dermatology : EJD
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 488-495
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808128211566985216